Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO

IPO Priced At Top Of Stock Price Band

Executive Summary

Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.

You may also be interested in...



South Korea's HK inno.N Targets Cell Therapy, Vaccine Expansion Following $500m IPO

South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.

Korea’s First Home-Grown COVID-19 Vaccine To Speed Hub Ambitions

Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.

China Rush Over? Korean Firms Step Up To Seize Opportunities

Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel